275 related articles for article (PubMed ID: 29861606)
1. Systemic therapy for cervical carcinoma - current status.
Serkies K; Jassem J
Chin J Cancer Res; 2018 Apr; 30(2):209-221. PubMed ID: 29861606
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
5. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
[TBL] [Abstract][Full Text] [Related]
6. Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
Kumar L; Gupta S
Oncology; 2016; 91 Suppl 1():8-17. PubMed ID: 27464068
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
8. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
[TBL] [Abstract][Full Text] [Related]
9. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B
Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
11. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for early-stage cervical cancer.
Asano H; Todo Y; Watari H
Chin J Cancer Res; 2016 Apr; 28(2):228-34. PubMed ID: 27199521
[TBL] [Abstract][Full Text] [Related]
14. Advances in cervical cancer pharmacotherapies.
Markman M
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):219-23. PubMed ID: 24490716
[TBL] [Abstract][Full Text] [Related]
15. Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation.
Heijkoop ST; van Doorn HC; Stalpers LJ; Boere IA; van der Velden J; Franckena M; Westermann AM
Int J Hyperthermia; 2014 Feb; 30(1):6-10. PubMed ID: 24156619
[TBL] [Abstract][Full Text] [Related]
16. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
18. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
19. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of current and emerging treatments for cervical cancer.
Duenas-Gonzalez A; Gonzalez-Fierro A
Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):671-682. PubMed ID: 31340683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
